Evaluating New Markers for Minimal Residual Disease Analysis by Flow Cytometry in Precursor B Lymphoblastic Leukemia

• DOI: 10.1007/s12288-017-0845-5
• Publication Date: 2017-07-03T09:24:46Z
• Authors: Sonal Jain; Anurag Mehta; Gauri Kapoor; Dinesh Bhurani; Sandeep Jain; Narendra Agrawal; Rayaz Ahmed; Dushyant Kumar
• Keywords: Minimal Residual Disease; Immunophenotyping; Cytometry; Hematology

Minimal residual disease is currently the most powerful prognostic indicator in Precursor B lymphoblastic leukemia. Multiparameter flow cytometry is the most commonly used modality. Seventy three B ALL cases and 15 normal marrows were evaluated for expression patterns of leukemia markers (CD38, CD58, CD73) in all 73 cases and CD66c, CD86 and CD123 in 23 cases. CD73 was aberrantly expressed in 90.41% cases and CD86 in 60.87% B ALL cases. Thus addition of these markers in MRD panels can increase the sensitivity of the assay.